InVivoMAb anti-mouse BTLA (CD272) BE0304-R100mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-mouse BTLA (CD272) Monoclonal Antibody has the following reported applications: in vivo BTLA+ B cell and CD4 T cell depletion*, Flow cytometry, *see description for details. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMAb anti-mouse BTLA (CD272)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0304-R100mg
Quantity100 mg
Applicationsin vivo BTLA+ B cell and CD4 T cell depletion*, Flow cytometry, *see description for details
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
Reactivitymouse
TargetBTLA
IsotypeIgG1, κ
Clone6F7
Hostmouse
NCBI Full Gene NameB and T lymphocyte associated
NCBI Gene AliasesA630002H24
ClonalityMonoclonal
ImmunogenIg domain of C57BL/6 mouse BTLA
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replicationJournal of immunology (Baltimore, Md. : 1950)October 1, 2011Zelinskyy G, Myers L, Dietze KK, Gibbert K, Roggendorf M, Liu J, Lu M, Kraft AR, Teichgräber V, Hasenkrug KJ, et al.

(2) BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic miceJournal of leukocyte biologyJuly 1, 2009Truong W, Hancock WW, Plester JC, Merani S, Rayner DC, Thangavelu G, Murphy KM, Anderson CC, Shapiro AM.

(3) A crucial role for HVEM and BTLA in preventing intestinal inflammationThe Journal of experimental medicineJune 9, 2008Steinberg MW, Turovskaya O, Shaikh RB, Kim G, McCole DF, Pfeffer K, Murphy KM, Ware CF, Kronenberg M.

(4) Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allograftsAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsDecember 1, 2007Truong W, Plester JC, Hancock WW, Merani S, Murphy TL, Murphy KM, Kaye J, Anderson CC, Shapiro AM.

(5) B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cellsJournal of immunology (Baltimore, Md. : 1950)March 15, 2005Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM.

Be the First to Write a Review!